|
Date
|
Title
(click to view the full text) |
|
11/14/08
|
InterMune to Present at Lazard Capital Markets Healthcare Conference
|
|
11/10/08
|
Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
|
|
11/7/08
|
InterMune to Present at Deutsche Bank Biotech Boston Confab
|
|
11/6/08
|
InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
|
|
10/28/08
|
InterMune to Release Third Quarter 2008 Financial Results on November 6
|
|
10/16/08
|
InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
|
|
9/24/08
|
InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
|
|
9/8/08
|
InterMune to Present at Baird Small Cap Healthcare Conference
|
|
9/2/08
|
InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
|
|
8/29/08
|
InterMune to Present at Thomas Weisel Partners Healthcare Conference
|
|
8/7/08
|
InterMune to Present at Canaccord Adams Conference
|
|
7/31/08
|
InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
|
|
7/30/08
|
InterMune to Present at BMO Healthcare Conference
|
|
7/24/08
|
InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
|
|
6/20/08
|
InterMune to Present at Jefferies Healthcare Conference
|
|
6/6/08
|
InterMune to Present at Goldman Sachs Healthcare and Needham & Co. Biotechnology and Medical Technology Conferences
|
|
5/29/08
|
InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
|
|
5/19/08
|
InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
|
|
5/16/08
|
InterMune to Present at Citigroup Healthcare Conference
|
|
5/9/08
|
InterMune to Present at Bank of America Health Care Conference
|
|
5/1/08
|
InterMune Reports First Quarter 2008 Financial Results and Business Highlights
|
|
4/30/08
|
InterMune to Present at Deutsche Bank Health Care Conference
|
|
4/24/08
|
InterMune to Release First Quarter 2008 Financial Results on May 1
|
|
4/21/08
|
InterMune Announces Progress on Pirfenidone in IPF
|
|
4/2/08
|
InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
|
|
4/1/08
|
InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
|
|
3/18/08
|
Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
|
|
3/12/08
|
InterMune to Present at Cowen and Company and Lehman Brothers Health Care Conferences
|
|
2/28/08
|
InterMune to Present at the SIGnificant Options in Healthcare Conference
|
|
2/7/08
|
InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
|
|
1/24/08
|
InterMune to Release Fourth Quarter, Full Year 2007 Financial Results on February 7
|
|
1/23/08
|
InterMune to Present at the 2008 Wachovia Healthcare Conference
|
|
1/7/08
|
InterMune Announces Continuing Progress on ITMN-191 (R7227)
|
|
1/2/08
|
InterMune to Present at the 26th Annual JPMorgan Healthcare Conference
|
|
11/26/07
|
InterMune Buys Out License Agreement for Pirfenidone
|
|
11/1/07
|
InterMune Announces Third Quarter 2007 Financial Results and Business Highlights
|
|
10/31/07
|
InterMune to Present at CIBC Healthcare Conference
|
|
10/22/07
|
InterMune to Release Third Quarter 2007 Financial Results on November 1
|
|
9/26/07
|
InterMune Announces Closing of Public Offering of Common Stock
|
|
9/26/07
|
InterMune Announces Start of Phase 1b Trial of ITMN-191
|
|
9/21/07
|
InterMune Announces Pricing of $68 Million Public Offering of Common Stock
|
|
9/18/07
|
InterMune Announces Proposed Public Offering of Common Stock
|
|
9/6/07
|
Louis Drapeau Elected to InterMune Board of Directors
|
|
9/4/07
|
InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
|
|
8/30/07
|
InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
|
|
8/2/07
|
InterMune Announces Second Quarter 2007 Financial Results and Business Highlights
|
|
7/24/07
|
InterMune Submits CTA Amendment for ITMN-191 and Provides Update on Clinical Development Program
|
|
6/22/07
|
InterMune to Present at the Jefferies Healthcare Conference
|
|
6/8/07
|
InterMune to Present at the Goldman Sachs 28th Annual Global Healthcare Conference
|
|
5/21/07
|
InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive Disease Week Meeting
|
|
5/17/07
|
InterMune to Present at the Citigroup 2007 Healthcare Conference
|
|
5/16/07
|
InterMune Completes Patient Enrollment in Phase 3 'Capacity' Program Evaluating Pirfenidone in Patients With IPF
|
|
5/3/07
|
InterMune Announces First Quarter 2007 Financial Results and Business Highlights
|
|
4/27/07
|
InterMune to Present at the 2007 Deutsche Bank Health Care Conference
|
|
4/26/07
|
InterMune to Release First Quarter 2007 Financial Results on May 3
|
|
4/11/07
|
InterMune Presents Research on ITMN-191 in Hepatitis C at EASL Annual Meeting
|
|
4/4/07
|
InterMune to Present at the CIBC Biotechnology and Specialty Pharmaceuticals Conference
|
|
3/20/07
|
InterMune Updates Expense Forecasts and Development Plans
|
|
3/15/07
|
InterMune to Extend Filing Date for Annual Report on Form 10-K
|
|
3/5/07
|
InterMune Discontinues Phase 3 INSPIRE Trial of Actimmune in Idiopathic Pulmonary Fibrosis
|
|
2/23/07
|
InterMune to Present at the SIGnificant Investment Options in Healthcare Conference
|
|
2/8/07
|
InterMune Announces Fourth Quarter and Full Year 2006 Financial Results
|
|
1/25/07
|
InterMune to Release Fourth quarter, Full Year 2006 Financial Results on February 8
|
|
1/25/07
|
InterMune to Present at the Wachovia Securities 2007 Healthcare Conference
|
|
1/9/07
|
InterMune Achieves Manufacturing Milestone in HCV Collaboration With Roche
|
|
1/4/07
|
InterMune to Present at the JPMorgan Healthcare Conference
|
|
12/28/06
|
InterMune Announces Filing of Shelf Registration Statement
|
|
12/19/06
|
InterMune Initiates Phase 1a Clinical Trial Evaluating Hepatitis C Protease Inhibitor ITMN-191 in Collaboration with Roche
|
|
11/30/06
|
InterMune to Present at the BMO Capital Markets Focus on Healthcare Conference
|
|
11/8/06
|
InterMune to Present at the ThinkEquity Partners ThinkTank
|
|
11/6/06
|
InterMune to Present at the CIBC World Markets Healthcare Conference
|
|
11/2/06
|
InterMune Closes Collaboration Agreement With Roche
|
|
10/30/06
|
InterMune Presents at Two Liver Disease Conferences Research on ITMN-191 in Hepatitis C
|
|
10/26/06
|
InterMune Announces Third Quarter Financial Results and Business Highlights
|
|
10/25/06
|
InterMune to Present at the C.E. Unterberg, Towbin Life Sciences Conference
|
|
10/24/06
|
InterMune to Present Research on ITMN-191 in Hepatitis C at Two Liver Disease Conferences
|
|
10/24/06
|
InterMune Presents Preclinical Data Showing Additive Anti-Fibrotic Combination Effects of Actimmune and Pirfenidone
|
|
10/16/06
|
InterMune Announces Conference Call and Webcast to Discuss Collaboration Agreement with Roche
|
|
10/16/06
|
Roche and InterMune Sign Agreement to Collaborate on the Research, Development and Commercialization of Hepatitis C Protease Inhibitors
|
|
10/6/06
|
InterMune to Release Third Quarter 2006 Financial Results on October 26
|
|
9/26/06
|
InterMune Submits Clinical Trial Authorization Application for ITMN-191 for Hepatitis C Infections
|
|
9/21/06
|
InterMune Elects Lars Ekman, M.D., Ph.D. to Board of Directors
|
|
9/20/06
|
InterMune to Present at the UBS Global Life Sciences Conference
|
|
9/6/06
|
InterMune to Present at the Bear Stearns Healthcare Conference and the ThinkEquity Partners Growth Conference
|
|
8/31/06
|
InterMune to Present at the Thomas Weisel Partners Healthcare Conference
|
|
7/31/06
|
InterMune Appoints John C. Hodgman as Chief Financial Officer
|
|
7/27/06
|
InterMune Announces Second Quarter Financial Results
|
|
7/10/06
|
InterMune to Release Second Quarter 2006 Financial Results on July 27
|
|
6/22/06
|
InterMune to Present at the Jefferies Life Sciences Conference
|
|
6/6/06
|
InterMune to Present at the Pacific Growth Equities Conference & the Needham Biotechnology and Medical Technology Conference
|
|
5/23/06
|
InterMune Presents New Preclinical Data on Its HCV Protease Inhibitor at Digestive Disease Week
|
|
5/22/06
|
InterMune Presents Preclinical Data for Actimmune(R) and Pirfenidone at American Thoracic Society Conference
|
|
5/17/06
|
InterMune Announces HCV Protease Inhibitor Presentations at Digestive Disease Week
|
|
5/17/06
|
InterMune Announces Presentations on Actimmune(R) and Pirfenidone at American Thoracic Society Conference
|
|
5/10/06
|
InterMune to Present at the Bank of America 2006 Health Care Conference
|
|
5/8/06
|
InterMune Presents Preclinical Data Identifying a Principal Mechanism of Anti-Fibrotic Action for Pirfenidone
|
|
4/27/06
|
InterMune Announces First Quarter Financial Results and Business Highlights
|
|
4/27/06
|
InterMune Initiates Phase III Program Evaluating Pirfenidone in Patients With IPF
|
|
4/26/06
|
InterMune to Present at the Deutsche Bank 2006 Health Care Conference
|
|
4/18/06
|
InterMune Completes Enrollment of the Phase III INSPIRE Trial
|
|
4/6/06
|
InterMune to Release First Quarter 2006 Financial Results on April 27
|
|
3/16/06
|
InterMune to Present at the Bear Biotech West Coast Confab
|
|
3/2/06
|
InterMune to Present at the 5th Annual JMP Securities Research Conference
|
|
2/2/06
|
InterMune Announces Fourth Quarter and Year End 2005 Financial Results
|
|
2/2/06
|
InterMune Discontinues Ovarian Cancer Trial
|
|
1/12/06
|
InterMune to Release Fourth Quarter & Year-End 2005 Financial Results on February 2
|
|
1/5/06
|
InterMune to Present at the 24th Annual JPMorgan Healthcare Conference
|
|
1/3/06
|
InterMune Completes Divestiture of Infergen(R) for up to $135.5 Million in Cash
|
|
12/27/05
|
InterMune Announces Divestiture of Oritavancin
|
|
12/1/05
|
InterMune Elects David S. Kabakoff, Ph.D. To Board Of Directors
|
|
11/28/05
|
InterMune Sharpens Focus on Key Development Programs and Significantly Strengthens Financial Position
|
|
11/14/05
|
InterMune Announces Clinical Data Presented at AASLD That Support Phase III DIRECT Trial for HCV
|
|
11/14/05
|
InterMune Presents HCV Protease Inhibitor Data at AASLD
|
|
11/9/05
|
InterMune Enrolls 600th Patient in Phase III INSPIRE Clinical Trial
|
|
11/8/05
|
InterMune Announces Presentations at the 56th Annual Meeting of the American Association for the Study of Liver Diseases
|
|
11/1/05
|
InterMune Presents In Vitro Data at Annual Meeting of the American College of Chest Physicians
|
|
10/27/05
|
InterMune Announces Third Quarter Financial Results and Business Highlights
|
|
10/20/05
|
InterMune Announces Presentations at Annual Meeting of the American College of Chest Physicians
|
|
10/17/05
|
InterMune Provides Update on Its Two Phase III Pulmonology Programs
|
|
10/14/05
|
InterMune to Release Third Quarter Financial Results on October 27
|
|
9/21/05
|
InterMune Announces Webcast of Corporate Presentation at the UBS Global Life Sciences Conference
|
|
9/8/05
|
InterMune Announces Webcast of Corporate Presentation at the ThinkEquity Partners Growth Conference
|
|
9/7/05
|
Intermune Announces Issuance of Two Composition of Matter Patents for Actimmune(R)
|
|
7/28/05
|
InterMune Announces Second Quarter Financial Results
|
|
7/19/05
|
InterMune and Array BioPharma Expand Hepatitis C Drug Discovery Collaboration
|
|
7/12/05
|
InterMune to Release Second Quarter Financial Results on July 28
|
|
7/11/05
|
InterMune Completes Enrollment of the Phase III DIRECT Trial Evaluating Daily Infergen Plus Ribavirin in PEG-Nonresponders
|
|
6/2/05
|
InterMune Announces Webcast of Corporate Presentation at the Pacific Growth Equities Life Sciences Conference
|
|
5/24/05
|
InterMune Announces Divestiture of Amphotec
|
|
5/23/05
|
Data Presented at ATS 2005 Support Intermune's Current Phase III Trial Design Evaluating Actimmune(R) in IPF Patients
|
|
5/16/05
|
InterMune Announces Presentation of Clinical Data From Studies of Daily Infergen With and Without Ribavirin for the Treatment of HCV
|
|
5/16/05
|
InterMune Announces Presentation of Data on Infergen Plus Actimmune for the Treatment of HCV PEG-Nonresponders
|
|
5/16/05
|
InterMune Announces Presentation of Specificity and Tolerability Data for Two Novel Protease Inhibitor Drug Candidates
|
|
5/9/05
|
InterMune Reaches Preliminary Settlement Agreement for Shareholder Class Action Lawsuit
|
|
5/9/05
|
InterMune Announces Hepatitis C Presentations at Digestive Disease Week
|
|
5/9/05
|
InterMune Announces Presentations on Actimmune and IPF at ATS 2005
|
|
5/2/05
|
Promising Results From Phase II Study of Pirfenidone in IPF Patients
|
|
4/28/05
|
InterMune Announces First Quarter Financial Results
|
|
4/7/05
|
InterMune to Release First Quarter Financial Results on April 28
|
|
3/29/05
|
InterMune Provides an Update on Pirfenidone Development Plans
|
|
3/9/05
|
InterMune Announces Webcast of Corporate Presentation at the SG Cowen & Co. 25th Annual Health Care Conference
|
|
2/23/05
|
Intermune Announces Webcast of Corporate Presentation at the Wells Fargo 2005 Healthcare Conference
|
|
2/23/05
|
InterMune Announces Webcast of Corporate Presentation at the JMP Securities 4th Annual Research Conference
|
|
2/18/05
|
InterMune Announces Management Appointment
|
|
2/7/05
|
InterMune Announces Fourth Quarter and Year End Financial Results
|
|
1/25/05
|
InterMune to Release Fourth Quarter and Year-End 2004 Financial Results on February 7
|
|
1/10/05
|
InterMune Announces Webcast of Corporate Presentation at the JPMorgan Healthcare Conference
|
|
1/10/05
|
Largest Completed IPF Study Points to Survival as Key Endpoint in Future Actimmune Studies
|
